Imprimis Pharmaceuticals reported a net income of $2.5 million, or $0.12 per share, in 2018’s second quarter, compared to a net income of $1.48 million, or $0.07 per share, in the second quarter of 2017.
The company’s revenues increased 51% year-over-year to $10.4 million, with ophthalmology-related revenues increasing 74% to $8.3 million, according to a company press release.
General and administrative costs increased from $6.5 million in 2017’s second quarter to $6.8 million in 2018’s second quarter.
Research and development costs decreased from $101,000 to $72,000 for
Uncategorized